What is the clinical evidence from this study?

Study design: Observational. Population: Type 1 Diabetes Mellitus (n=427). Intervention: Positivity for ≥2 cardiac autoantibodies vs. Positivity for ≤1 cardiac autoantibodies. Primary outcome: CVD events (nonfatal myocardial infarction, stroke, death resulting from CVD, heart failure, or coronary artery bypass graft) (HR 16.1, 95% CI 3.0-88.2).

What does this research mean for the field?

Positivity for two or more cardiac autoantibodies in patients with type 1 diabetes is associated with a markedly increased long-term risk of cardiovascular events, suggesting an autoimmune mechanism for cardiovascular disease in this population. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This research explores the link between glycemic control and cardiac autoimmunity in type 1 diabetes mellitus and its implications for cardiovascular disease risk.

July 25, 2026CirculationOpen Access

Multiple cardiac autoantibodies in T1D predict ~1510% higher cardiovascular event risk.

View Full Paper

Ask AI

Bookmark

Why the study?

Does poor glycemic control and subsequent cardiac autoimmunity increase the long-term risk of cardiovascular disease in patients with type 1 diabetes mellitus?

Population

427 participants, including Type 1 Diabetes Mellitus patients from the DCCT trial with mean HbA1c ≥9.0% and…

Comparison

Poor glycemic control and presence of ≥2 cardiac… vs Good glycemic control and presence of ≤1 cardiac…

Design

Cohort

Follow-up

26-year median follow-up

Key result

Positivity for ≥2 cardiac autoantibodies in type 1 diabetes was associated with a markedly increased risk of cardiovascular events (HR 16.1; 95% CI 3.0-88.2) over a 26-year median follow-up.

Authors

GSGiovane Rodrigo Sousa DPDavid Pober AGAlfonso Galderisi

Discussion

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Her group has also shown that poor glycemic control in patients with type 1 diabetes — but not in those with type 2 diabetes — was associated with cardiac autoimmunity. An unexpected finding was the similar cardiac autoantibody levels in the patients with type 1 diabetes, who were young adult and without diabetes complications, and a heart failure cohort with Chagas' cardiomyopathy, which is thought to be caused by chronic inflammation of the heart muscle ('myocarditis'), raising the possibility of a subclinical autoimmune-associated myocardial dysfunction in type 1 diabetes”

Joslin Diabetes CenterNews Coverage

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Heart failure in particular has recently been recognized as an important complication of type 1 with national register-based studies showing tenfold increased risk of heart failure in individuals with poor glycemic control. In addition, there's a higher case fatality rate in type 1 than type 2 diabetes, which suggests different mechanisms for heart failure might be involved in type 1 diabetes.”

Joslin Diabetes CenterNews Coverage

Overview

May link hyperglycemia to CVD via cardiac autoimmunity in T1DM; hypothesis-generating, needs prospective validation before clinical consideration.

Key Points

This research explores the link between glycemic control and cardiac autoimmunity in type 1 diabetes mellitus and its implications for cardiovascular disease risk.
Analyzed longitudinal samples from the DCCT with participants categorized by HbA1c levels (≥9.0% and ≤7.0%).
Measured coronary artery calcification and high-sensitivity C-reactive protein over a median follow-up of 26 years.
Compared cardiac autoantibodies in type 1 diabetes participants with those in type 2 diabetes and Chagas cardiomyopathy patients.
HbA1c ≥9.0% group had significantly higher cardiac autoantibodies levels (P < 0.001).
Positivity for ≥2 cardiac autoantibodies was linked to a notable hazard ratio of 16.1 for cardiovascular events (95% CI, 3.0–88.2).
Increased high-sensitivity C-reactive protein levels were observed in patients with ≥2 cardiac autoantibodies (6.0 mg/L vs. 1.4 mg/L; P = 0.003).

Study Design

Type

Observational (n=427)

Structured PICO

Does poor glycemic control and subsequent cardiac autoimmunity increase the long-term risk of cardiovascular disease in patients with type 1 diabetes mellitus?

Population

427 participants including T1DM patients with mean HbA1c ≥9.0% or ≤7.0%, matched T2DM patients, and Chagas cardiomyopathy controls, followed for a median of 26 years.

Exposure

Poor glycemic control (mean HbA1c ≥9.0%) and presence of ≥2 cardiac autoantibodies (AAbs)

Comparator

Good glycemic control (mean HbA1c ≤7.0%) and presence of ≤1 cardiac AAbs

Outcome

Prevalence and profiles of cardiac autoantibodies (AAbs), subsequent coronary artery calcification, high-sensitivity C-reactive protein, and CVD events (composite of nonfatal myocardial infarction, stroke, death resulting from CVD, heart failure, or coronary artery bypass graft)composite

Main Result

Hazard Ratio: 16.1 (95% CI 3–88.2)

Poor glycemic control in type 1 diabetes mellitus is associated with the development of cardiac autoimmunity, which strongly predicts long-term cardiovascular disease risk decades later.

Cite This Study

Sousa et al. (2019) conducted an observational in Type 1 Diabetes Mellitus (n=427). Positivity for ≥2 cardiac autoantibodies vs. Positivity for ≤1 cardiac autoantibodies was evaluated on CVD events (nonfatal myocardial infarction, stroke, death resulting from CVD, heart failure, or coronary artery bypass graft) (HR 16.1, 95% CI 3.0-88.2). Positivity for ≥2 cardiac autoantibodies in type 1 diabetes was associated with a markedly increased risk of cardiovascular events (HR 16.1; 95% CI 3.0-88.2) over a 26-year median follow-up.

synapsesocial.com/papers/6a647f8e7ac8de810e7eb65c https://doi.org/10.1161/circulationaha.118.036068

View Full Paper

Ask AI

Bookmark

July 25, 2026CirculationOpen Access

Multiple cardiac autoantibodies in T1D predict ~1510% higher cardiovascular event risk.

View Full Paper

Ask AI

Bookmark

Why the study?

Does poor glycemic control and subsequent cardiac autoimmunity increase the long-term risk of cardiovascular disease in patients with type 1 diabetes mellitus?

Population

427 participants, including Type 1 Diabetes Mellitus patients from the DCCT trial with mean HbA1c ≥9.0% and…

Comparison

Poor glycemic control and presence of ≥2 cardiac… vs Good glycemic control and presence of ≤1 cardiac…

Design

Cohort

Follow-up

26-year median follow-up

Key result

Positivity for ≥2 cardiac autoantibodies in type 1 diabetes was associated with a markedly increased risk of cardiovascular events (HR 16.1; 95% CI 3.0-88.2) over a 26-year median follow-up.

Authors

GSGiovane Rodrigo Sousa DPDavid Pober AGAlfonso Galderisi

Discussion

Member takes

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Her group has also shown that poor glycemic control in patients with type 1 diabetes — but not in those with type 2 diabetes — was associated with cardiac autoimmunity. An unexpected finding was the similar cardiac autoantibody levels in the patients with type 1 diabetes, who were young adult and without diabetes complications, and a heart failure cohort with Chagas' cardiomyopathy, which is thought to be caused by chronic inflammation of the heart muscle ('myocarditis'), raising the possibility of a subclinical autoimmune-associated myocardial dysfunction in type 1 diabetes”

Joslin Diabetes CenterNews Coverage

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Heart failure in particular has recently been recognized as an important complication of type 1 with national register-based studies showing tenfold increased risk of heart failure in individuals with poor glycemic control. In addition, there's a higher case fatality rate in type 1 than type 2 diabetes, which suggests different mechanisms for heart failure might be involved in type 1 diabetes.”

Joslin Diabetes CenterNews Coverage

Overview

May link hyperglycemia to CVD via cardiac autoimmunity in T1DM; hypothesis-generating, needs prospective validation before clinical consideration.

Key Points

This research explores the link between glycemic control and cardiac autoimmunity in type 1 diabetes mellitus and its implications for cardiovascular disease risk.
Analyzed longitudinal samples from the DCCT with participants categorized by HbA1c levels (≥9.0% and ≤7.0%).
Measured coronary artery calcification and high-sensitivity C-reactive protein over a median follow-up of 26 years.
Compared cardiac autoantibodies in type 1 diabetes participants with those in type 2 diabetes and Chagas cardiomyopathy patients.
HbA1c ≥9.0% group had significantly higher cardiac autoantibodies levels (P < 0.001).
Positivity for ≥2 cardiac autoantibodies was linked to a notable hazard ratio of 16.1 for cardiovascular events (95% CI, 3.0–88.2).
Increased high-sensitivity C-reactive protein levels were observed in patients with ≥2 cardiac autoantibodies (6.0 mg/L vs. 1.4 mg/L; P = 0.003).

Study Design

Type

Observational (n=427)

Structured PICO

Does poor glycemic control and subsequent cardiac autoimmunity increase the long-term risk of cardiovascular disease in patients with type 1 diabetes mellitus?

Population

427 participants including T1DM patients with mean HbA1c ≥9.0% or ≤7.0%, matched T2DM patients, and Chagas cardiomyopathy controls, followed for a median of 26 years.

Exposure

Poor glycemic control (mean HbA1c ≥9.0%) and presence of ≥2 cardiac autoantibodies (AAbs)

Comparator

Good glycemic control (mean HbA1c ≤7.0%) and presence of ≤1 cardiac AAbs

Outcome

Main Result

Hazard Ratio: 16.1 (95% CI 3–88.2)

Poor glycemic control in type 1 diabetes mellitus is associated with the development of cardiac autoimmunity, which strongly predicts long-term cardiovascular disease risk decades later.

Cite This Study

synapsesocial.com/papers/6a647f8e7ac8de810e7eb65c https://doi.org/10.1161/circulationaha.118.036068

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark